Newsroom

SHANGHAI--(BUSINESS WIRE)--VeriSilicon (688521.SH) today announced that its VC9800D video processing IP supports AV2 decoding....

中国上海--(BUSINESS WIRE)--(美国商业资讯)-- 芯原股份（芯原，股票代码：688521.SH）今日宣布其VC9800D视频处理（VPU）IP已支持AV2解码，进一步扩展了公司面向下一代视频与流媒体应用的先进视频编解码IP组合。VC9800D支持在广泛的智能消费电子及多媒体设备中灵活部署新一代视频技术。芯原已向全球多家客户提供支持AV2的VC9800D IP，并基于正式发布的AV2 V1.0规范持续优化该IP。 AV2是开放多媒体联盟（Alliance for Open Media, AOMedia）推出的新一代视频编码规范，其在AV1基础上进一步提升了视频压缩效率，可在显著降低码率的同时实现高质量视频传输。该标准针对流媒体、广播电视及实时视频会议等各类不断演进的应用场景进行了优化。 芯原的VC9800D具备高度可配置的视频处理能力，可支持独立AV2解码，或与多种视频格式灵活组合配置，以满足不同系统的集成需求。除AV2外，该IP还支持多种先进视频格式，包括AVC/H.264、HEVC/H.265、VVC/H.266、AVS2、AVS3、VP9及AV1，可广泛兼容全球多...

MINNEAPOLIS--(BUSINESS WIRE)--ZimCal Asset Management through BIMIZCI Fund LLC provides a longer response to Medallion Financial’s inaccurate and misleading June 4, 2026 press release, which was transparently designed to manipulate stockholders and publicly sully ZimCal’s and its nominees’ reputations. We have already issued a Rebuttal Deck that comprehensively disproved recycled attacks from MFIN. Unlike MFIN we have relied on data and the actual written record. But the inflammatory and inaccu...

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in PicS N.V. (“PicS” or the “Company”) (NasdaqGS: PICS) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors of PicS who were adversely affected if they purchased the Company’s Class A common stock in and/or traceable to its January 30, 2026 initial public offering...

ニューオーリンズ--(BUSINESS WIRE)--（ビジネスワイヤ） -- Diabetology Limited（ジャージー島）は、ニューオーリンズで開催の米国糖尿病学会（ADA）第86回年次学術集会におけるポスター発表1724-P（https://diabetology.co.uk/ada-poster）で、Oraglutide™に関する初のヒトデータを報告しています。Oraglutide™は、独自の「Axcess™」送達技術を用いて製剤化された、腸管内で放出される小型カプセル型の経口セマグルチド製剤です。 主なポイント 6日間の血糖コントロール：Oraglutide™ 4 mgを単回経口投与したところ、血糖値は持続的に低下し、6日目にも14%の低下が認められました（p=.046）。この6日間という効果持続期間は、ヒトを対象とした静脈内ブドウ糖負荷試験（IVGTT）において、経口GLP-1製剤を単回投与した際にこれまでに報告された中で最長です。 インスリン分泌が28%増加：プラセボと比較して、インスリンAUC（%）は投与日（0日目）に12%（p=0.02）、1日目に28%（p...

NEW ORLEANS--(BUSINESS WIRE)--Posterpresentatie van Diabetology Limited (Jersey) (https://diabetology.co.uk/ada-poster) 1724-P tijdens de ADA 86e Scientific Session, New Orleans, rapporteert de eerste menselijke gegevens van Oraglutide™ — klein pilletje in de darm vrijkomende orale semaglutide, samengesteld aan de hand van de eigen Axcess™-afgiftetechnologie. BELANGRIJKSTE HOOGTPUNTEN 6-daagse glucosecontrole: één enkele orale dosis van 4 mg Oraglutide™ produceerde een aanhoudende glucoseverlag...

NEW ORLEANS--(BUSINESS WIRE)--La presentazione poster di Diabetology Limited (Jersey) (https://diabetology.co.uk/ada-poster) 1724-P alla 86a Sessione scientifica dell'ADA, a New Orleans, ha illustrato i primi dati umani su Oraglutide™, una piccola capsula di semaglutide orale rilasciata a livello intestinale, formulata utilizzando la tecnologia di rilascio proprietaria Axcess™. PUNTI SALIENTI Controllo del glucosio in 6 giorni: un'unica dose orale da 4 mg di Oraglutide™ ha prodotto una riduzion...

NOVA ORLEANS--(BUSINESS WIRE)--Diabetology Limited (Jersey) (https://diabetology.co.uk/ada-poster) 1724-P na 86ª Sessão Científica da ADA, em Nova Orleans, relatando os primeiros dados em humanos do Oraglutide™ — semaglutida oral de liberação intestinal em pequenas cápsulas, formulada com a tecnologia proprietária de administração Axcess™. PRINCIPAIS DESTAQUES Controle glicêmico por 6 dias: Uma única dose oral de 4 mg de Oraglutide™ produziu uma queda sustentada na glicose. Medindo 14% no 6º di...

PHILADELPHIA--(BUSINESS WIRE)--WhiteHawk Income Corporation (“WhiteHawk Minerals” or the “Company”) today announced the pricing of the upsized initial public offering of 7,700,000 shares of its Class A common stock at a price to the public of $26.00 per share. The 7,700,000 share offering represents a 775,000 share upsize to the originally proposed 6,925,000 share offering. The Company has granted the underwriters a 30-day option to purchase up to an additional 1,155,000 shares of its Class A c...

NUEVA ORLEANS--(BUSINESS WIRE)--Presentación de Diabetology Limited (Jersey) de póster 1724-P (https://diabetology.co.uk/ada-poster) en la 86.ª Sesión Científica de la American Diabetes Association (ADA), celebrada en Nueva Orleans, con los primeros datos en humanos de Oraglutide™, una semaglutida oral de liberación intestinal en cápsulas pequeñas, formulada con la tecnología de administración patentada Axcess™. ASPECTOS DESTACADOS Control de glucosa durante 6 días: una dosis oral única de 4 mg...